UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Gabriella Linville-Engler - Investor Relations Dave Hering - Chief Financial Officer Pete Schmidt - Chief Medical Officer Conference Call Participants Maxwell Skor - Morgan Stanley Evan Wang - Guggenheim Patrick Trucchio - H.C. Wainwright Operator Welcome to the Invivyd Second Quarter 2023 Business and Financial Results Update Call. I will now turn the call over to Gabriella Linville-Engler, Directo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1403134 (State or other jurisdiction of incorporation or organization) 1601 Trapelo Road, Suite 178 Waltham, MA 02451 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR/ 15(d) OF THE SECURITIES EXCHANGE ACT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-14 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40703 INVIVYD, INC. (Exact name of Registrant as specified in its Charter) Delaware 85-1403134 (State or other jurisdiction of Indica ...

FORWARD LOOKING STATEMENTS All trademarks in this presentation are the property of their respective owners. 2 2 INVIVYD No vaccine alternatives for prevention • 116 million adults in U.S. with comorbidities7 VYD222 is an investigational product candidate not approved for use in any country. The safety and efficacy of VYD222 have not been established. VYD INVIVYD Continuous monitoring of viral evolution coupled with rapid antibody discovery and engineering to address the evolving SARS-CoV-2 threat Monitor va ...

Financial Data and Key Metrics Changes - Operating expenses for Q3 2022 were $34.1 million, down from $49.4 million in Q3 2021, attributed to the wind down of clinical trials and manufacturing activities [35] - SG&A expenses increased to $13.2 million in Q3 2022 from $11.1 million in Q3 2021, due to higher public company costs and professional services [37] - The net loss for Q3 2022 was $45.1 million, compared to $60.4 million in Q3 2021, with a basic and diluted net loss per share of $0.42 versus $0.98 in the prior year [37] - The company ended Q3 2022 with cash, cash equivalents, and marketable securities totaling $419 million, expected to fund operations into Q2 2024 [38] Business Line Data and Key Metrics Changes - The company is advancing its proprietary combination anti-SARS-CoV-2 receptor binding domain (RBM) candidate, NVD 200, into clinical development [16] - NVD 200 is a reengineered version of Adintrevimab, demonstrating retained in vitro activity against current and emerging variants [16][49] Market Data and Key Metrics Changes - The annual market for COVID-19 prevention and treatment is estimated to be between $80 billion and $100 billion, with the company aiming to capture a portion of this revenue [33] Company Strategy and Development Direction - The company focuses on continuous innovation and the development of a suite of antibody therapies to address ongoing viral evolution [12][22] - The integrated discovery platform is seen as a competitive advantage, allowing for rapid engineering of antibodies to meet emerging viral threats [23] Management's Comments on Operating Environment and Future Outlook - Management emphasized the ongoing need for effective COVID-19 treatments, particularly for vulnerable populations such as the immunocompromised [32] - The company is committed to addressing the continuous health toll of COVID-19 and sees significant opportunities for shareholder value creation through innovation [32] Other Important Information - The company plans to update its cash runway guidance after completing its 2023 budget [38] - Management highlighted the importance of speed in developing new candidates in response to rapidly evolving variants [52] Q&A Session Summary Question: Clinical trial design for NVD 200 - Management acknowledged the dynamic nature of the clinical landscape and indicated that NVD 200 will enter the clinic in Q1 2023, with ongoing data expected throughout the year [42][43] Question: Neutralization activity of NVD 200 against emerging variants - Management confirmed that in vitro testing shows NVD 200 retains activity against current and emerging variants, validating the company's approach [49][50] Question: Speed of developing new candidates - Management stated that the company has demonstrated the ability to rapidly generate clinical data and is focused on staying ahead of viral evolution [52][53] Question: Conversations with regulators regarding surrogate markers - Management indicated that while specific conversations with regulators are not disclosed, there is a recognized need for increased speed in product development [57][58] Question: Prioritization of prevention versus treatment - Management emphasized that prevention is the highest priority, especially for underserved populations like the immunocompromised [60]

INVIVYD Corporate Presentation November 2022 Transcending the limitations of the immune system Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "po ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-40703 INVIVYD, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 8 ...

INVIVYD Investor Presentation September 2022 Transcending the limitations of the immune system Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," " ...